| ATYR PHARMA INC. DL -,001 |
| USA |
| Gesundheit |
| US0021202025 / A2PM86 |
| 471A (Frankfurt) / ATYR (NASDAQ) |
| FRA:471A, ETR:471A, 471A:GR, NASDAQ:ATYR |
| - |
| https://www.atyrpharma.co.. |
|
aTyr Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines based on tRNA synthetase biology. The company’s current work centers on efzofitimod, a selective NRP2 modulator being studied for interstiti..
>Volltext.. |
| 32.35 Mio. EUR |
| -8.23 Mio. EUR |
| 0.17 Mio. EUR |
| -54.74 Mio. EUR |
| -53.45 Mio. EUR |
| -0.55 EUR |
| 9.93 Mio. EUR |
| 14.21 Mio. EUR |
| -47.94 Mio. EUR |
| 5.04 |
| - |
| 5.88% |
| - |
| - |
| - |
| - |
| ATYR |
| 25.09.26 |
|